Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA

BACKGROUND: Randomized phase III trials have established the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as first-line treatment for EGFR mutation-positive advanced non–small-cell lung cancer (EGFR Mut+ NSCLC). This retrospective cohort study examined the managemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yulin, Appius, Anita, Pattipaka, Thirupathi, Feyereislova, Andrea, Cassidy, Adrian, Ganti, Apar Kishor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319739/
https://www.ncbi.nlm.nih.gov/pubmed/30608948
http://dx.doi.org/10.1371/journal.pone.0209709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319739/
https://www.ncbi.nlm.nih.gov/pubmed/30608948
http://dx.doi.org/10.1371/journal.pone.0209709

Ejemplares similares